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Available online 7 October 2014AbstractRadioembolization with yttrium-90 microspheres offers an alternative treatment option for patients with unresectable intrahepatic chol-
angiocarcinoma (ICC). However, the rarity and heterogeneity of ICC makes it difficult to draw firm conclusions about treatment efficacy.
Therefore, the goal of the current study is to systematically review the existing literature surrounding treatment of unresectable ICCs with
yttrium-90 microspheres and provide a comprehensive review of the current experience and clinical outcome of this treatment modality. We
performed a comprehensive search of electronic databases for ICC treatment and identified 12 studies with relevant data regarding radio-
embolization therapy with yttrium-90 microspheres. Based on pooled analysis, the overall weighted median survival was 15.5 months.
Tumour response based on radiological studies demonstrated a partial response in 28% and stable disease in 54% of patients at three
months. Seven patients were able to be downstaged to surgical resection. The complication profile of radioembolization is similar to
that of other intra-arterial treatment modalities. Overall survival of patients with ICC after treatment with yttrium-90 microspheres is higher
than historical survival rates and shows similar survival to those patients treated with systemic chemotherapy and/or trans-arterial chemo-
embolization therapy. Therefore, the use of yttrium-90 microspheres should be considered in the list of available treatment options for ICC.
However, future randomized trials comparing systemic chemotherapy, TACE and local radiation will be required to identify the optimal
treatment modality for unresectable ICC.
Crown Copyright  2014 Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/3.0/).
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Intrahepatic cholangiocarcinoma (ICC) is a malignant
transformation of cholangiocytes within the hepatic paren-
chyma. The incidence of this primary liver malignancy is
increasing,1,2 and ICC accounts for up to 15% of primary
liver cancers.3 In contrast to the other two locations ofthor. Box 202, Level 9, University Department of
’s Hospital, Cambridge CB2 0QQ, United Kingdom.
1; fax: þ44 (0) 1223 20762523.
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yright 2014 Published by Elsevier Ltd. This is an open accholangiocarcinoma (hilar and distal bile duct), intrahepatic
lesions are often asymptomatic and, therefore, present as an
incidental mass lesion without jaundice or other stigmata of
biliary obstruction.4 Given the asymptomatic nature of
many ICCs, patients often present with locally advanced tu-
mours. Although surgery offers the highest curative poten-
tial, many tumours are deemed unresectable at the time of
diagnosis.5 Patients with unresectable ICC have a median
survival of less than eight months.6,7 Systemic chemo-
therapy with gemcitabine and cisplatin offers an overall
survival advantage in patients with advanced biliary
cancer8; however, given the aggressive nature ofcess article under the CC BY license (http://creativecommons.org/licenses/
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ment modalities are being investigated.9e11
Radioembolization with yttrium-90 microspheres offers
an alternative radiotherapy option for primary and second-
ary intrahepatic tumours.12 In this treatment modality, b-
emitting yttrium-90 microspheres are injected into the he-
patic artery feeding the tumour, become trapped in the
tumour and emit local internal radiation. The advantage
of radioembolization is the ability to deliver high dose radi-
ation to the tumour with minimal collateral damage to the
normal liver parenchyma or surrounding tissues.13 In
contrast, non-selective external beam radiation has higher
rates of radiation-induced liver disease as normal hepatic
tissue is radiated in addition to the tumour. Recently,
yttrium-90 radioembolization for the treatment of hepato-
cellular carcinoma showed a longer time-to-progression
and fewer side-effects than trans-arterial delivered chemo-
therapy protocols.14,15 In addition, high response rates
were seen with radioembolization treatment of intrahepatic
neuroendocrine tumours.16,17
Patients with unresectable cholangiocarcinoma have
limited treatment options with only modest survival advan-
tages.8,11 Local therapy with yttrium-90 microspheres of-
fers the promise of delivering a high dose of radiation
directly to the tumour, thereby causing increased tumour
destruction. Treatment of ICCs with radioembolization
has been attempted; however, only small trials have been
performed with this novel treatment. In addition, the rela-
tive rarity of ICCs and heterogeneity of this disease makes
it difficult to draw firm conclusions about treatment effi-
cacy. The goal of the current study is to systematically re-
view the existing literature surrounding treatment of
unresectable ICCs with yttrium-90 microspheres with the
aim of providing a comprehensive review of the current
experience and clinical outcome of this treatment modality.
MethodsInclusion criteria for considering studies for this
review
Study characteristics
Given the rarity of yttrium-90 radioembolization treat-
ment for unresectable ICC, studies with greater than one
patient were included in order to ensure the comprehensive
capture of the available clinical experience. This included
human case-series (>1 case), randomized controlled trials,
non-randomized controlled trials, prospective cohort series.
Participants
The target population consists of adult (>18 years old)
male or female patients with unresectable ICC.
Interventions
The intervention under study is radioembolization ther-
apy with yttrium-90 microspheres. The yttrium-90microsphere treatment may be performed before, synchro-
nously, or after systemic chemotherapy.Outcome measures
Primary outcomes
The primary outcomes are overall survival and radiolog-
ical response to radioembolization therapy with yttrium-90
microspheres.
Secondary outcomes
The secondary outcomes of this study are the ability of
yttrium-90 treatment to convert unresectable cholangiocar-
cinoma to resectable, mortality, and morbidity.Search methods for identification of studies
Electronic searches
Published English-language manuscripts were consid-
ered for review with inclusion from 2000 to 2013. A
comprehensive search of electronic databases (e.g., MED-
LINE, EMBASE, SCOPUS, BIOSIS Previews and the Co-
chrane Library) using broad search terms was completed.
The bibliographies of all included articles were examined
to identify additional potentially relevant publications.
Search terms included unresectable intrahepatic cholangio-
carcinoma, advanced biliary tract cancer, microsphere,
SIR-Spheres, Selective Internal Radiation, TheraSphere,
yttrium-90, radioembolization and radiation lobectomy.Data collection and analysis
Selection of studies
All studies involving radioembolization therapy with
yttrium-90 microspheres for unresectable ICCs were
included. Given the rarity of studies focussing on yttrium-
90 microsphere treatment, manuscripts published in ab-
stract form were included. A dedicated search for the
full-length manuscripts of published abstracts was also un-
dertaken. A trained librarian conducted the electronic
searches (X.S.), and one author (D.A.) conducted a pre-
screen to identify the articles clearly irrelevant articles by
title, abstract and keywords of publication. Following
this, three independent reviewers (R.G., S.A. and D.A.) as-
sessed the studies for relevance, inclusion, and methodolog-
ical quality. Articles were classified as either:
1 Relevant (meeting all specified inclusion criteria);
2 Possibly relevant (meeting some but not all inclusion
criteria);
3 Rejected (not relevant to the review).
Three reviewers (R.G., S.A. and D.A.) independently re-
viewed full-text versions of all studies classified as relevant
or possibly relevant. Disagreements were resolved by re-
extraction, when necessary. In the cases of numerous
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tion with the corresponding authors of those studies was
undertaken to ensure the uniqueness of the patients in
each study.
Data extraction and management
Two reviewers (D.A. and X.S.) independently extracted
data from the full versions of the manuscripts. The ex-
tracted information included details of methods (e.g.,
randomization, blinding, etc.), demographics (e.g., age,
sex, etc.), treatment characteristics (e.g. target dose, num-
ber of treatments, etc.), clinical characteristics of each
group, study inclusion and exclusion criteria, number of pa-
tients excluded and lost to follow-up, baseline and post-
intervention outcomes (e.g., median survival, etc.), mortal-
ity/morbidity data (e.g., death, abdominal pain, length of
hospital stay, etc.) and methods of analysis.
Statistical analysis
Pooled analysis was performed on the data from
included studies. Descriptive statistics (simple counts,
means, and medians) were used to report study, patient-
and treatment-level data. The number of patients enrolled
was used in the calculation of study and patient demo-
graphics. Efficacy outcomes of interest were synthesized
by pooling data for patients that underwent therapy
involving radioembolization with yttrium-90 microspheres.
Due to the high heterogeneity among the studies and lack
of randomized controlled trials, a meta-analysis was not
deemed appropriate. Statistical calculations were per-
formed using Stata 10 (StataCorp LP, USA) and weighted
overall survival and response analysis were performed us-
ing Prism 5 (GraphPad Software, San Diego, CA).
ResultsResults of the searchA total of 203 articles were identified using our search
criteria for screening (Fig. 1). Following assessment by
our exclusion criteria, 105 were rejected and 94 studies re-
mained for abstract review. Following abstract review, 50
studies were excluded and 44 studies remained for full-
text eligibility assessment. 12 primary studies meeting the
inclusion criteria were identified following thorough assess-
ment of the complete manuscripts18e29 (Table 1). These
included seven prospective case series19,20,22,24e26,28 and
five retrospective cohort studies.18,21,23,27,29Included studies11 of the 12 included studies contained median survival
data for patients undergoing radioembolization therapy
with yttrium-90 microspheres for the treatment of unresect-
able ICC. Outcome data on mortality, morbidity and compli-
cations were available from eight included studies. Baselinecharacteristics of patients in the included studies are pro-
vided in Table 1. A total of 298 patients were assessed in
the 12 studies and numbers of patients in each study ranged
between 2 and 46. The weighted mean age of the patients
was 62.1 years, ranging from 57 to 68. The patients had a
median follow-up of 10.8 months (range: 6e29 months).Characteristics of patients and radioembolization
therapy with yttrium-90 microspheresDetails of radioembolization therapy with yttrium-90
microspheres are provided in Table 2. The majority of pa-
tients included in the analysis had previously undergone
some form of treatment for their ICC prior to radioemboli-
zation. Most of these patients previously received chemo-
therapy (54%) and/or underwent surgical resection (33%).
Once patients were deemed refractory to chemotherapy or
had unresectable recurrences after initial surgical resection,
they were then considered for radioembolization therapy. It
was unclear from most studies if chemotherapy was given
during or after radioembolization therapy. There was no
preference to the type of yttrium-90 delivery system (glass
or resin) used to treat the ICC. Based on four included
studies, the weighted mean number of treatments per pa-
tient was 1.5 with a weighted mean dose of 1.6 GBq.Primary and secondary outcomesThe primary outcome, survival, was assessed as median
survival. Overall weighted median survival was 15.5
months (range: 7e22.2), based on 11 included studies
(Table 3). One study,27 did not statistically reach a median
survival because data censoring did not allow the survival
curve to go below 0.55. However, the mean survival of
17.7 months was close to where the median survival would
be should another event occur. Therefore, the nine patients
in this study were included in the pooled analysis.
Most commonly, the response evaluation criteria in solid
tumours (RECIST) was reported. RECIST is defined as
complete response (disappearance of all target lesions), par-
tial response (decrease 30% in the sum in the greatest
dimension of target lesions), stable disease (decease
<30% or increase <20% in sum in greatest dimension of
target lesions) and progressive disease (increase 20% in
sum in greatest dimension of target lesions and/or progres-
sion of non-target lesion).28 Due to the small number of
studies that reported RECIST, these studies were pooled
with those reporting the modified (m)RECIST and Positron
emission tomography response evaluation criteria in solid
tumour (PERCIST; Table 3). Once these studies were
pooled, radiological response for solid tumours was re-
ported in six studies. A weighted mean partial response
was seen in 28% and stable disease was seen in 54% of pa-
tients at three months.
Secondary outcomes included the ability to convert un-
resectable to resectable disease, mortality, overall
Figure 1. PRISMA flow diagram showing selection of articles for review.
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ity to offer surgical resection to previously unresectable dis-
ease was reported in three studies.24,25,28 Combined, these
studies had a total 73 patients, and surgery was performed
on seven patients post-radioembolization. Mortality data
was specifically reported in three included studies, and of
these, there was one treatment-related death. Overall
morbidity was reported in eight included studies and is
summarized in Table 4. The most common types of
morbidity following radioembolization therapy with
yttrium-90 microspheres were fatigue (33%), abdominal
pain (28%) and nausea (25%).
Discussion
Locally delivered radiation with yttrium-90 micro-
spheres is a novel therapy for patients with unresectable
ICC who, otherwise, have limited treatment options. The
published experience with radioembolization for the treat-
ment of cholangiocarcinoma is narrow, and of these studies,
few document survival outcomes. Furthermore, there are no
trials directly comparing the efficacy of yttrium-90 micro-
spheres to other available treatment options, such assystemic chemotherapy or transarterial chemotherapy
(TACE). Therefore, in this study, we systematically re-
viewed the existing literature surrounding treatment of un-
resectable ICCs with yttrium-90 microspheres.
The primary outcomes of this review are survival and
radiological response after treatment with local radiation.
The overall median survival of patients with unresectable in-
trahepatic cholangiocarcinoma is 15.5 months from the initi-
ation of yttrium-90 microsphere therapy. Since there were
no randomized comparative trials in this review, it is difficult
to compare survival with yttrium-90 microspheres to sur-
vival after other treatments. However, recently published
data show the overall survival of unresectable ICC after sys-
temic cisplatin-gemcitabine chemotherapy is 11.7 months8
and survival after treatment with TACE is 13.4 months.30
All of these results are higher than historical survival times
of less than eight months.6,7 Taken together, the results of
radioembolization are promising as an alternative therapy
for patients with unresectable ICC. However, randomized
controlled trials will be required to determine the optimal
treatment or combination treatment modality.
As with all systematic reviews, the quality of the com-
bined results is dependent on the quality of the original
Table 1
Study design and baseline characteristics within included studies for systematic review.
Reference Publication
year
Country Study interval Publication type Study design Number of
patients
Age
(years)a
Gender
(% male)
Diagnosis Liver involved
Bower and
Little
2013 Australia 2002e2012 Abstract Retrospective
cohort
23 62.5 48 ICC 10e70%
Camacho
et al.
2013 USA NA Abstract Prospective
cohort
21 NA NA ICC NA
Camacho
et al.
2013 USA NA Abstract Prospective
cohort
9 58 56 ICC NA
Chaiteerakij
et al.
2011 USA 2000e2009 Abstract Retrospective
cohort
20 NA NA ICC NA
Hoffmann
et al.
2012 Germany 2007e2010 Full manuscript Prospective
cohort
33 65.2 54.5 ICC þ mets <50%
Hyder et al. 2013 USA 1992e2012 Full manuscript Retrospective
cohort
46 NA 48 ICC þ mets Tumour >5 cm
Martinez
et al.
2013 NA 2012 Abstract Prospective
cohort
2 NA NA ICC NA
Mouli et al. 2013 USA 2003e2011 Full manuscript Prospective
cohort
46 68 54 ICC þ mets <25%
Prajapati
et al.
2012 USA 2002e2012 Abstract Prospective
cohort
24 NA NA ICC NA
Saxena
et al.
2010 Australia 2004e2009 Full manuscript Prospective
cohort
25 57 52 ICC þ mets <50%
Shridhar
et al.
2012 USA 2009e2011 Abstract Retrospective
cohort
40 NA NA ICC þ mets NA
Turkmen
et al.
2013 Turkey 2008e2012 Full manuscript Retrospective
cohort
9 NA NA ICC þ mets <70%
NA. not available; ICC. intrahepatic cholangiocarcinoma; mets. metastatic disease present.
a Mean.
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analysis is from a heterogeneous population. Some patients
underwent systemic chemotherapy prior to yttrium-90
microsphere treatment and some underwent systemic
chemotherapy during treatment, however, we only reported
survival since the initiation of the yttrium-90 treatment.
Therefore, the overall pooled survival may underestimate
the effects of radioembolization if some patients have
already undergone previous therapy. One study29 highlights
this point: the one-year overall survival for patients treatedTable 2
Treatment characteristics within included studies.
Reference 90-Yttrium microsphere Treatments per patient
Bower and Little NA 1.04
Camacho et al. Resin NA
Camacho et al. Resin NA
Chaiteerakij et al. NA 1.55
Hoffmann et al. Resin 1.03
Hyder et al. NA NA
Martinez et al. Resin NA
Mouli et al. Glass 2
Prajapati et al. Resin NA
Saxena et al. Resin NA
Shridhar et al. Glass NA
Turkmen et al. Glass and Resin NA
GBq, gigabecquerel; NA, not available; Gy, Grey.
a Range.
b Mean.
c Radiation dose reported in Gy, therefore, was not included in weighted analywith first-line radioembolization was 84.6% compared to
20.2% for those treated with salvage therapy. This study
also has the lowest median survival of all included studies.
In contrast, selection and publication bias could overesti-
mate the effects of yttrium-90 microspheres treatment,
especially in retrospective cohort studies.
Tumour response using RECIST,22,25,28 mRECIST21 or
other radiological criteria18,19 was reported in six included
studies. In these studies, at three months, partial response
was seen in 28% of patients by imaging criteria and stableDose (GBq) Other cancer therapy
0.7e2.19a Chemotherapy at discression of oncologist
NA All patients post-chemotherapy (refractory)
NA All patients post-chemotherapy (refractory)
NA NA
1.54b 78.8% post-chemotherapy, 36.6% post-surgery
NA 27.8% post-chemotherapy. 11.6% post-surgery
NA NA
3.9 Gyb,c 35% post-chemotherapy, 11% post-surgery
1.68b All patients post- chemotherapy (refractory)
1.76b 72% post-chemotherapy, 40% post-surgery
NA 48% post-chemotherapy, 8% post-surgery
NA All patients post-chemotherapy (refractory)
sis.
Table 3
Radiological response and survival following treatment with 90-Yttrium microspheres.
Reference Radiology
criteria
Response at 3 months (%) Follow-upa
(months)
Survivala (months) Comments
Complete Partial Stable Progress
Bower and Little NA NA 34.7 21.7 NA NA 7
Camacho et al. mRECIST NA NA NA NA NA 16.3 (7.2e25.4)
Camacho et al. PERCIST 22.2 33.3 33.3 11.1 NA 21.7
Chaiteerakij et al. mRECIST 0 100b 0 NA 14.6  3.9
Hoffmann et al. RECIST 0 36.4 51.5 15.2 10 22
Hyder et al. mRECIST 3.1c 22.4c 61.5c 13c NA 11.3
Martinez et al. RECIST NAc NAc NAc NAc NA NA 1 downstaged to surgery
Mouli et al. WHO 0 25 73 2 29 5.3 (n ¼ 10) 14.4 (n ¼ 36) 5 downstaged to surgery
Prajapati et al. RECIST NA NA NA NA NA 11.5
Saxena et al. RECIST NA 24 48 20 8.1 9.3 1 downstaged to surgery
Shridhar et al. NA NA NA NA NA 6 7.4
Turkmen et al. NA NAc NAc NAc NAc NA mean 17.7  3.2
NA, not available; (m)RECIST, (modified) response evaluation criteria in solid tumours; PERCIST, PET response evaluation criteria in solid tumours; WHO,
World Health Organization.
a Median and range or SE, except where indicted.
b Partial and stable responses were pooled.
c Radiological response grouped with other intra-arterial treatment modalities.
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were only reported in one study where this response was
seen in two of nine patients.19 However, it should be noted
that this is also the only study that used positron emission
tomography imaging and response evaluation criteria in
solid tumours (PERCIST) criteria to evaluate tumour
response.
A potential benefit of radiotherapy with yttrium-90 mi-
crospheres is the conversion of unresectable to resectable
disease. Surgical resection of previously inoperable disease
occurred in seven patients in three different studies. In the
study by Mouli et al.,25 five patients of their cohort of 46Table 4
Complications following treatment with 90-Yttrium microspheres.
Reference Morbidity (%)
Mortality Fatigue Abdominal pain Fever Nausea
Bower and Little 0 0 0 0 0
Camacho et al. NA NA NA NA NA
Camacho et al. NA NA NA NA NA
Chaiteerakij et al. NA 39 13 0 NA
Hoffmann et al. 0 NA 84.8 NA 60.6
Hyder et al. NA 17 12 3 6
Martinez et al. NA NA NA NA NA
Mouli et al. NA 54 28 NA 22
Prajapati et al. NA 17 17 NA NA
Saxena et al. 1 64 40 NA 16
Shridhar et al. NA 15 8 NA NA
Turkmen et al. NA NA NA NA NA
NA, not available; bili, billirubin; AST, aspartate transaminase: Alk Phos, alkaliunderwent surgical resection post-treatment with yttrium-
90 microspheres. With a median follow-up of over 2.5
years after surgical resection, all five patients were alive.
All patients were treatment na€ıve prior to treatment with
yttrium-90 microspheres. Martinez et al.24 reported one pa-
tient who underwent surgical resection post-
radioembolization and had no evidence of recurrent or re-
sidual disease; however, the length of follow-up was not
specified. The positive results of surgical resection in these
studies are in accordance with surgical resection offering
the highest survival benefit for patients with ICC.6,7
Although there is the probability of publication bias, thereEnzyme increases (%) Other complications/Comments
Jaundice Bili AST Alk Phos
0 NA NA NA
NA NA NA NA
NA NA NA NA
NA 35 NA 93
NA 69.7 54.5 NA
2 NA NA NA Complications grouped with
other modes of intra-arterial
therapies
NA NA NA NA
NA 7 NA NA 1 Gastroduodenal ulcer,
2 pleural effusions,
7 ascites
NA 8.3 NA NA 1 Duodenal ulcer
NA 8 0 4 1 Duodenal ulcer,
1 Pulmonary Embolism,
4 ascites,
2 pleural effusion
5 NA NA NA 2 Acute radiation hepatitis,
1 chronic radiation hepatitis
NA NA NA NA
ne phosphatase.
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downsize tumours to resectability in a minority of patients.
Therefore, a potential indication for radioembolization
therapy is in cases of borderline resectable tumours at
initial presentation.
The overall morbidity and mortality of patients undergo-
ing radioembolization therapy was reported in eight of the
12 included studies (Table 4). Only one death was reported
in all of the included studies.28 Serious morbidity requiring
intervention or long-term sequelae included complications
of ulcers (due to bead migration), pleural effusions and as-
cites. The majority of morbidity was from fever, abdominal
pain and nausea. Overall, the complication profile of radio-
embolization is similar to that of chemoembolization seen
in recent systematic reviews of similar disease process.30,31
Radioembolization-induced liver disease (jaundice and
ascites appearing 1e2 months after radioembolization in
the absence of tumour progression or bile duct occlusion32)
was not specifically mentioned in any study. However, a
number of studies did report cases of ascites and hepatitis
post-radioembolization, which may indicate
radioembolization-induced liver damage did occur. This
disease is especially common in radioembolization therapy
patients who have previously undergone systemic chemo-
therapy (which the majority of patients in this review
have). Recently, modified radioembolization protocols
have been designed to decrease the risk of liver damage
post-radioembolization and it is recommended that sys-
temic chemotherapy be delayed by two months.32
There are some limitations to the current study. First,
five studies were retrospective cohorts which carry the pos-
sibility of selection bias. Second, seven included studies
were published in abstract form only. Due to their concise
nature, abstract publications provide only limited informa-
tion regarding treatment, follow-up and outcomes. In addi-
tion, abstract publications may have not undergone the
same stringent peer-review process that a full manuscript
has. A dedicated search for the full manuscript of the
included abstracts was performed, however, none were
found. Third, there is heterogeneity between included
studies and no standardized reporting of results. Differ-
ences across studies include the type of yttrium-90 radia-
tion microspheres, radiation doses and the length of time
of the cohort study. In addition, and likely due to the rela-
tive rarity of unresectable ICC, the population within
studies is also dissimilar. This heterogeneity includes both
patient factors (presence of metastatic disease and size of
tumour) and treatment factors (prior chemotherapy or sur-
gical intervention and concomitant chemotherapy). Last,
although the search for studies to include in the pooled
analysis was stringent, it is possible that some relevant
studies were missed.
The pooled analysis of radioembolization therapy with
yttrium-90 microspheres for the treatment of unresectable
ICC in this study demonstrates an overall survival of 15.5
months. This is higher than historical survival6 and is similarto survival with systemic chemotherapy8 and TACE ther-
apy.30 There is the potential for tumour resectability post-
local radiation therapy and the side effect profile is also
similar to that seen with TACE therapy for the same dis-
ease.30 Therefore, the use of yttrium-90 microspheres
should be considered in the list of available treatment op-
tions for ICC. However, future randomized trials comparing
systemic chemotherapy, TACE and local radiation will be
required to identify the optimal treatment modality for unre-
sectable cholangiocarcinoma. In addition, the creation of a
treatment registry with standardized criteria has been rec-
ommended by the Brachytherapy Oncology Consortium.33
Report standardization may also allow any synergistic ef-
fects from the concomitant use of chemotherapy and
Yittrim-90 radiation microspheres to be identified.
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